Agonist monoclonal anti-CD40 antibodies can act on DCs and immature myeloid cells to increase their antigen-presenting capacity, maturation and activation potential (called licensing), thereby shifting the balance from tolerance to anti-tumor immunity40,43,44. This evidence concerns the gene CD40 and neoplasm.